A once-a-day pill could transform the lives of migraine sufferers after it was given the green light for NHS use. The National Institute for Health and Care Excellence (NICE) has recommended a ...
Pfizer's $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff after the European Commission approved the drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback